2025 Volume: 01 Issue: 07 www.ijrpa.com ISSN 2456-9995 Review Article

International Journal Research Publication Analysis

Page: 01-23

APPLICATION OF QUALITY BY DESIGN (QBD) PRINCIPLES IN THE DEVELOPMENT OF LIPOSOMAL DRUG DELIVERY SYSTEMS: A COMPREHENSIVE REVIEW

***Mahesh P. Kattimani, Seema Bansode, Pranit Kale**

Department of Quality Assurance Late Laxmibai Phadtare College of Pharmacy, Indapur, Pune- 413114.

Article Received: 26 October 2025

Article Revised: 14 November 2025

Published on: 05 December 2025

***Corresponding Author: Mahesh P. Kattimani**

Department of Quality Assurance Late Laxmibai Phadtare College of Pharmacy, Indapur, Pune- 413114. DOI: https://doi-doi.org/101555/ijrpa.5783

ABSTRACT

The integration of Quality by Design (QbD) into pharmaceutical research has provided a structured and scientifically driven pathway for developing liposomal drug delivery systems with enhanced safety, efficacy, and reproducibility. Liposomes, as versatile nanocarriers, can significantly improve the solubility, stability, and bioavailability of both synthetic and herbal drugs. This review provides a comprehensive overview of QbD principles and their application in the systematic design, optimization, and control of liposomal formulations. Key elements such as Quality Target Product Profile (QTPP), Critical Quality Attributes (CQAs), Critical Material Attributes (CMAs), and Critical Process Parameters (CPPs) are discussed in detail, along with the role of Design of Experiments (DoE) in establishing a robust design space. Representative case studies including curcumin, doxorubicin, and silymarin-loaded liposomes demonstrate the effectiveness of QbD in achieving optimized formulations with superior therapeutic outcomes. The discussion also encompasses challenges, regulatory expectations, and the future integration of Artificial Intelligence (AI), machine learning, and Process Analytical Technology (PAT) for real-time process monitoring. Overall, this review underscores the significance of QbD as a transformative tool in nano pharmaceutical development, promoting reproducibility, scalability, and regulatory compliance in the formulation of next-generation liposomal and herbal nanomedicines.

KEYWORDS: Quality by Design (QbD); Liposomes; Nanocarriers; Design of Experiments (DoE); Critical Quality Attributes (CQAs);

Graphical Abstract-



1. INTRODUCTION-

Over the past few decades, nanotechnology has revolutionized the field of pharmaceutical sciences by offering innovative delivery systems capable of overcoming major limitations associated with conventional dosage forms. Among various nanocarriers, liposomes have gained significant attention due to their ability to encapsulate both hydrophilic and lipophilic drugs, improve solubility, enhance bioavailability, and enable targeted drug delivery. Liposomes are spherical vesicles composed of one or more phospholipid bilayers that mimic biological membranes, making them biocompatible and versatile for a wide range of therapeutic applications. Despite these advantages, the reproducibility, stability, and scalability of liposomal formulations remain critical challenges. [(1)] Variations in formulation parameters such as lipid composition, cholesterol ratio, hydration time, and processing conditions can significantly influence key quality attributes, including particle size, zeta potential, encapsulation efficiency, and release kinetics. These challenges underscore the need

for a systematic approach to formulation development that ensures product quality through scientific understanding rather than empirical trial and error. In response to these challenges, the Quality by Design (QbD) concept, introduced by the U.S. Food and Drug Administration (FDA) and formalized through ICH guidelines Q8 to Q11, has emerged as a cornerstone of modern pharmaceutical development. [2] QbD emphasizes a proactive, risk-based, and science-driven approach to design, development, and manufacturing, wherein the product's quality is built into the process from the very beginning. The approach integrates critical elements such as the Quality Target Product Profile (QTPP), Critical Quality Attributes (CQAs), Critical Material Attributes (CMAs), and Critical Process Parameters (CPPs) to establish a robust design space and ensure consistent product performance. Applying QbD principles to liposomal formulations allows researchers to gain a deeper understanding of how formulation and process variables interact to affect final product quality. Through the use of Design of Experiments (DoE) and risk assessment tools, optimal formulation parameters can be determined with fewer experimental runs, leading to cost-effective and time-efficient development. Furthermore, QbD provides a regulatory framework that supports lifecycle management, continuous improvement, and enhanced product reliability. [3]

Therefore, this review aims to present a comprehensive overview of the application of QbD principles in liposomal drug delivery systems, highlighting its impact on formulation optimization, process control, regulatory compliance, and product performance. The discussion will cover the fundamental concepts of QbD, its critical components, and its implementation in liposomal design, supported by relevant case studies and future perspectives in the field of nanotechnology-based drug delivery.

2. Liposomal Drug Delivery Systems: An Overview

2.1 Structure and Composition

Liposomes are microscopic spherical vesicles composed of one or more concentric phospholipid bilayers surrounding an aqueous core. [4] Their amphiphilic nature enables the encapsulation of both hydrophilic and lipophilic molecules hydrophilic drugs partition into the aqueous compartment, while lipophilic compounds are incorporated within the lipid bilayer. The primary structural components include phospholipids (such as phosphatidylcholine, phosphatidylethanolamine, or phosphatidylserine) and cholesterol, which enhances membrane rigidity and stability. [5]



Fig. 1. Liposome Structure.

Depending on the method of preparation and composition, liposomes can vary widely in size (20 nm to several micrometers) and lamellarity (unilamellar or multilamellar). The surface properties of liposomes can be further modified by incorporating polymers (e.g., PEGylation), ligands (e.g., antibodies, peptides), or charge modifiers to achieve long-circulating, targeted, or stimuli-responsive behavior. This structural flexibility allows liposomes to serve as a platform for delivering diverse classes of therapeutic agents, including small molecules, peptides, proteins, vaccines, and nucleic acids. [6]

2.2 Classification of Liposomes

Liposomes are classified based on various parameters such as size, number of bilayers, composition, and method of preparation: [7,8]

Type	Characteristic	Example / Use
Small Unilamellar Vesicles (SUVs)	Single bilayer, 20–100 nm	Targeted delivery, rapid clearance
Large Unilamellar Vesicles (LUVs)	Single bilayer, 100–1000 nm	Controlled release systems
Multilamellar Vesicles	Multiple bilayers	Depot formulations

(MLVs)		
Stealth Liposomes	PEG-coated, long-circulating	Doxil® (Doxorubicin)
Cationic Liposomes	Positively charged for gene/drug delivery	DNA, siRNA formulations
pH- or Thermo-sensitive Liposomes	Release triggered by external stimuli	Tumor or inflamed tissue targeting

This diversity enables the design of liposomal systems tailored for specific routes of administration and therapeutic objectives.

2.3 Advantages of Liposomal Drug Delivery Systems

Liposomes offer numerous pharmaceutical and therapeutic advantages that make them one of the most successful nanocarrier systems:

1. **Enhanced Bioavailability:** Improve solubility and absorption of poorly water-soluble drugs.
2. **Targeted Delivery:** Enable passive (EPR effect) or active (ligand-mediated) targeting of diseased tissues.
3. **Reduced Toxicity:** Encapsulation of cytotoxic drugs reduces exposure to healthy cells.
4. **Controlled Release:** Provide sustained or stimuli-responsive drug release profiles.
5. **Biocompatibility and Biodegradability:** Phospholipids are naturally occurring molecules, minimizing immunogenicity.
6. **Versatile Drug Loading:** Capable of carrying hydrophilic, lipophilic, and amphiphilic compounds simultaneously.

These attributes have led to the successful clinical translation of several liposomal formulations, including Doxil® (doxorubicin), AmBisome® (amphotericin B), and DepoDur™ (morphine sulfate). [9]

2.4 Limitations and Challenges

Despite significant advancements, liposomal systems face multiple challenges that limit their widespread application: [10]

- **Physical Instability:** Liposomes are prone to aggregation, fusion, and leakage of encapsulated drug during storage.
- **High Production Cost:** Manufacturing processes (e.g., extrusion, homogenization) can be expensive and difficult to scale up.

- **Batch-to-Batch Variability:** Slight changes in processing parameters can cause large variations in particle size and entrapment efficiency.
- **Short Shelf Life:** Oxidation and hydrolysis of phospholipids reduce long-term stability.
- **Regulatory Complexity:** Quality assurance and reproducibility are critical due to complex formulation–process interactions. [11,12]

These challenges highlight the necessity of adopting Quality by Design (QbD) frameworks to ensure consistent performance, robust manufacturing, and regulatory compliance. Integrating QbD principles helps identify Critical Quality Attributes (CQAs) and Critical Process Parameters (CPPs) that govern liposomal characteristics, facilitating optimization through statistical and risk-based approaches. [13]

3. Overview of Quality by Design (QbD)

3.1 Concept and Regulatory Background

The concept of Quality by Design (QbD) was introduced by the U.S. Food and Drug Administration (FDA) and formalized under the International Council for Harmonizations (ICH) guidelines Q8 to Q11, which emphasize a systematic approach to pharmaceutical development. Unlike traditional Quality by Testing (QbT where quality is verified by end-product testing QbD focuses on building quality into the product from the earliest stages of design and development. [14]

The central philosophy of QbD is that product quality should be ensured by understanding the relationship between formulation materials, process parameters, and critical attributes, rather than relying solely on final product testing. According to the ICH Q8(R2) guideline, QbD is defined as “a systematic approach to development that begins with predefined objectives and emphasizes product and process understanding and process control, based on sound science and quality risk management.”

Fig. 2. QbD Workflow Diagram (Flowchart)

This approach encourages the pharmaceutical industry to move from empirical development toward science- and risk-based formulation design, allowing for regulatory flexibility and continuous improvement. By incorporating QbD principles, developers can achieve robust, reproducible, and scalable products while meeting the stringent expectations of regulatory authorities such as the FDA and the European Medicines Agency (EMA).

3.2 Key Elements of QbD

The implementation of QbD in pharmaceutical product development involves several interrelated elements that guide formulation design and optimization:



Fig. 3. QTPP vs. CQA Mapping.

3.2.1 Quality Target Product Profile (QTPP)

The QTPP serves as a prospective summary of the quality characteristics desired in the final product. It includes parameters such as dosage form, route of administration, therapeutic dose, release profile, stability, and patient acceptability. The QTPP acts as a foundation for identifying the Critical Quality Attributes (CQAs) that directly influence the safety and efficacy of the product. (15)

3.2.2 Critical Quality Attributes (CQAs)

CQAs are physicochemical, biological, or microbiological properties that must be controlled within an appropriate range to ensure product quality. For liposomal formulations, CQAs typically include:

- Particle size and polydispersity index (PDI)
- Zeta potential
- Encapsulation efficiency (EE%)
- Drug loading capacity
- In vitro release rate
- Physical and chemical stability

These attributes are directly linked to the pharmacokinetic behavior and therapeutic performance of liposomes. (16)

3.2.3 Critical Material Attributes (CMAs)

CMAs refer to the key properties of raw materials (e.g., phospholipids, cholesterol, solvents, drug substances) that impact product CQAs. Variations in lipid purity, drug–lipid ratio, or hydration media can significantly affect the morphology, encapsulation, and release profile of liposomes. (17)

3.2.4 Critical Process Parameters (CPPs)

CPPs are process variables (e.g., temperature, mixing speed, sonication time, hydration duration, pH, solvent removal rate) that influence one or more CQAs. Understanding and controlling CPPs ensures that liposome characteristics remain within the design space and consistently meet QTPP targets. (18)

3.2.5 Design Space and Control Strategy

The Design Space represents the multidimensional combination of input variables (CMAs and CPPs) that have been demonstrated to assure quality. Operating within this space ensures product consistency, while movement outside it could result in quality deviations. A Control Strategy is then established to continuously monitor and manage these parameters during manufacturing. [19]

3.3 Role of Design of Experiments (DoE)

The Design of Experiments (DoE) is a key statistical tool within the QbD framework used to identify and quantify the relationships between input variables and output responses. DoE methods enable the systematic evaluation of multiple factors simultaneously, minimizing the number of experimental trials while maximizing information gain.

Commonly used DoE methodologies include:

- Full and Fractional Factorial Designs (for screening significant variables),
- Central Composite Design (CCD) and Box–Behnken Design (BBD) (for optimization), and
- Response Surface Methodology (RSM) (for modeling and prediction of optimal conditions).



Fig 4. Design of Experiments (DoE) concept for optimizing liposomal formulations.

DoE facilitates the construction of mathematical models that describe how CMAs and CPPs influence CQAs such as vesicle size, PDI, and encapsulation efficiency. These models guide the identification of optimal formulation conditions and the development of a robust design space. Software such as Design-Expert®, Minitab®, or JMP® is commonly employed for this purpose. [20]

3.4 Advantages of Implementing QbD

Implementing QbD offers multiple benefits throughout the drug development lifecycle:

- Enhances product and process understanding, leading to robust formulations.
- Reduces development time and cost by minimizing trial-and-error experimentation.
- Improves regulatory flexibility through well-documented design space justification.
- Facilitates scale-up and technology transfer.
- Enables continuous process verification (CPV) and lifecycle management.

Incorporating QbD principles into liposomal formulation development ensures consistent product quality, predictable performance, and compliance with global regulatory expectations, ultimately supporting safer and more effective therapeutics. [21]

4. Application of QbD in Liposomal Formulation Development

The application of Quality by Design (QbD) principles to liposomal formulations has transformed conventional, empirical formulation approaches into systematic, science-based development processes. Through the integration of QbD tools such as risk assessment and Design of Experiments (DoE), formulation scientists can identify, understand, and control the critical variables influencing liposome quality and performance. [22]

Liposomes are complex nanosystems whose characteristics depend on a delicate balance between formulation composition and manufacturing parameters. Small variations in lipid ratio, hydration conditions, or processing parameters can result in significant changes in particle size, encapsulation efficiency, and stability. Hence, applying QbD ensures robustness, reproducibility, and scalability of liposomal products. [23]

4.1 Defining the Quality Target Product Profile (QTPP)

The QTPP forms the foundation of QbD implementation by defining the desired quality attributes of the final liposomal product. For liposomes, the QTPP includes parameters such as:

- Route of administration (oral, parenteral, topical, pulmonary, etc.)
- Therapeutic indication and dose
- Desired release profile (immediate, sustained, or targeted release)
- Particle size and zeta potential range
- Stability and shelf-life requirements

For example, an intravenous liposomal system demands small, uniform vesicles (<200 nm) with a narrow polydispersity index (PDI < 0.3) and neutral or slightly negative zeta potential for enhanced circulation time and reduced opsonization. In contrast, an oral liposomal formulation may prioritize stability in the gastrointestinal environment and controlled drug release. [24]

4.2 Identification of Critical Quality Attributes (CQAs)

Once the QTPP is established, the next step involves identifying Critical Quality Attributes (CQAs) the physical, chemical, or biological properties that must be maintained within specific limits to ensure product performance and safety.

Typical CQAs for liposomal systems include:

- **Particle size and PDI** – influence biodistribution, stability, and drug release.
- **Zeta potential** – affects physical stability and cell–membrane interaction.
- **Encapsulation efficiency (EE%)** – determines drug loading and therapeutic dose.
- **Drug release rate** – impacts pharmacokinetic and pharmacodynamic profiles.
- **pH and osmolarity** – affect biocompatibility and tolerability.
- **Physical and chemical stability** – ensures product consistency during storage.

Control of these attributes ensures that liposomal formulations consistently meet therapeutic expectations and regulatory quality standards. [25]

4.3 Determination of Critical Material Attributes (CMAs) and Critical Process Parameters (CPPs)

Critical Material Attributes (CMAs) refer to the properties of input materials such as phospholipids, cholesterol, drug, and hydration medium that directly influence product CQAs. Similarly, Critical Process Parameters (CPPs) involve processing conditions (e.g., temperature, mixing speed, sonication amplitude) that affect liposomal formation and stability. [26]

Category	Example Parameters	Impact on CQAs
CMAs	Type and purity of phospholipid	Vesicle integrity and stability
	Cholesterol-to-lipid ratio	Membrane rigidity and EE%
	Drug–lipid ratio	Loading efficiency and release kinetics
	Hydration medium pH	Drug solubility and vesicle charge
CPPs	Hydration temperature and time	Vesicle size and uniformity
	Sonication or extrusion pressure	Particle size reduction and PDI
	Solvent evaporation rate	Lipid film homogeneity
	Mixing speed and duration	Entrapment efficiency and stability

Identifying and controlling these parameters are vital to maintaining liposomal quality and ensuring consistent performance during scale-up and manufacturing.

4.4 Design of Experiments (DoE) in Liposome Optimization

DoE serves as a cornerstone of QbD-based formulation design by enabling the systematic evaluation of multiple factors and their interactions. Rather than changing one variable at a time, DoE allows simultaneous variation of key CMAs and CPPs to determine their collective impact on CQAs. [27]

Several statistical designs are commonly employed in liposomal optimization:

- **Full factorial design** – to screen significant factors.
- **Central composite design (CCD)** and **Box–Behnken design (BBD)** – to optimize parameters and establish mathematical relationships.
- **Response surface methodology (RSM)** – to visualize the influence of factors and predict optimal conditions.

For example, in developing a liposomal formulation of curcumin, researchers applied a Box–Behnken design varying lipid-to-cholesterol ratio, sonication time, and hydration temperature to achieve optimal particle size, PDI, and EE%. The resulting model provided a design space ensuring reproducible product quality even during scale-up. Similar approaches have been successfully applied to silymarin, doxorubicin, and amphotericin B formulations, demonstrating the universality of QbD in liposomal optimization. [28]

4.5 Establishing the Design Space and Control Strategy

Based on DoE data and risk assessment, a design space is established a multidimensional region representing the combination of input variables (CMAs and CPPs) that yield an

acceptable product. Working within this design space ensures robust performance, while deviations beyond its limits may lead to product failure or variability. (29)

A control strategy is then developed to monitor and manage CMAs and CPPs during manufacturing and storage. This may include:

- **In-process controls** (e.g., temperature, pH, mixing speed monitoring).
- **Process Analytical Technology (PAT)** tools for real-time analysis (e.g., particle size tracking).
- **Post-manufacturing testing** to ensure CQAs remain within acceptance criteria.
  Establishing and maintaining a validated control strategy ensures the consistency, safety, and efficacy of liposomal formulations throughout their lifecycle. (30)

4.6 Benefits of QbD in Liposome Development

The integration of QbD in liposomal formulation offers numerous scientific and regulatory advantages:

- Ensures robustness and reproducibility of formulation characteristics.
- Enhances understanding of formulation–process interactions.
- Facilitates efficient scale-up and technology transfer.
- Reduces development cost and time by minimizing experimental iterations.
- Strengthens regulatory acceptance through transparent documentation of design space.

By implementing QbD, the development of liposomal formulations transitions from an empirical art to a structured, predictive science ensuring consistent quality and therapeutic performance. (31)

5. Case Studies and Examples of QbD in Liposomal Formulation Development

5.1 Overview

Over the past decade, numerous studies have demonstrated the effectiveness of applying Quality by Design (QbD) principles in optimizing liposomal drug delivery systems. These case studies illustrate how the systematic application of Design of Experiments (DoE) and risk assessment can enhance product robustness, therapeutic performance, and scalability. Both synthetic and herbal drug molecules have been explored under the QbD framework, although applications to phytoconstituents remain comparatively limited providing fertile ground for further research.

5.2 Case Study 1: QbD-Based Development of Curcumin-Loaded Liposomes

Objective: To enhance the solubility, stability, and bioavailability of curcumin, a hydrophobic polyphenolic compound with known antioxidant and anticancer properties.

Approach: A Box–Behnken Design (BBD) was employed to investigate the effects of phospholipid-to-cholesterol ratio, hydration temperature, and sonication time on the CQAs specifically, particle size, PDI, and encapsulation efficiency.

Findings:

- Optimal conditions yielded liposomes with particle size < 150 nm, PDI < 0.3, and EE% > 80%.
- QbD enabled prediction of formulation behavior within the established design space, ensuring batch-to-batch reproducibility.
- The optimized formulation showed a 3.5-fold increase in bioavailability compared to pure curcumin suspension.

Conclusion: This study demonstrated that the QbD framework provides a robust platform for optimizing complex parameters in curcumin liposomes, achieving improved stability and predictable performance. [32,33]

Reference: Patel et al., *International Journal of Pharmaceutics*, 2019.

5.3 Case Study 2: QbD-Guided Optimization of Doxorubicin Liposomes

Objective: To improve the stability and therapeutic efficacy of doxorubicin-loaded liposomes, a well-known anticancer formulation.

Approach: A Central Composite Design (CCD) was used to optimize lipid composition, drug-to-lipid ratio, and hydration time, while monitoring CQAs such as vesicle size, zeta potential, and drug release profile.

Findings:

- The optimized liposomes exhibited high encapsulation efficiency (~95%) and prolonged drug release over 48 hours.
- DoE allowed clear identification of CPP–CQA relationships, leading to a well-defined design space.
- The optimized formulation demonstrated enhanced cytotoxicity against breast cancer cells compared to free drug.

Conclusion: QbD-driven optimization improved both formulation quality and therapeutic outcome, validating the utility of QbD for parenteral liposomal products. [34,35]

Reference: Singh et al., *European Journal of Pharmaceutics and Biopharmaceutics*, 2021.

5.4 Case Study 3: Application of QbD in Herbal Liposomes Silymarin

Objective: To enhance the bioavailability and hepatoprotective activity of silymarin, a poorly soluble flavonolignan from *Silybum marianum*.

Approach: A risk assessment matrix (Ishikawa diagram) was used to identify critical variables influencing encapsulation efficiency and stability. DoE was employed to evaluate phospholipid concentration, drug-to-lipid ratio, and hydration pH as CPPs.

Findings:

- Optimized silymarin liposomes showed nanometric size (~120 nm), EE% above 85%, and improved stability under accelerated conditions.
- Pharmacokinetic studies revealed a 2.8-fold increase in oral bioavailability.
- The QbD approach established an optimized design space ensuring product reproducibility.

Conclusion: This study demonstrated how QbD principles can be effectively applied to herbal drug formulations, offering standardized and reproducible delivery systems for complex natural compounds. [36]

Reference: Sharma et al., *Pharmaceutics*, 2022.

5.5 Proposed Study: QbD-Based Development and Optimization of Ecliptine-Loaded Liposomes

Rationale: Ecliptine, a bioactive alkaloid derived from *Eclipta alba (Bhringraj)*, exhibits potent hepatoprotective and antioxidant activities. However, its poor solubility and instability have limited its clinical application. To date, no systematic QbD-based liposomal formulation has been reported for Ecliptine, representing a promising research opportunity. [37,38]

Proposed QbD Framework:

QbD Step	Description / Application to Ecliptine
QTPP	Oral or parenteral liposomal system for hepatoprotection.
CQAs	Particle size (<200 nm), PDI (<0.3), EE% (>80%), stability (>3 months).
CMAs	Phospholipid type, cholesterol ratio, solvent purity, hydration medium.

CPPs	Hydration time, temperature, sonication energy, pH of medium.
DoE Approach	Box–Behnken Design to evaluate main and interaction effects.
Design Space & Control Strategy	Defined ranges for CMAs/CPPs ensuring reproducible CQAs.

Expected Outcome:

- Significant enhancement in solubility, bioavailability, and liver targeting of Ecliptine.
- Establishment of a regulatory-compliant QbD framework for future phytoliposomal systems.
- Contribution to the limited literature on QbD in herbal liposome development.

Novelty:

This study would be the first comprehensive QbD-based liposomal formulation of Ecliptine, addressing both formulation optimization and mechanistic understanding.

5.6 Summary of Case Studies

Drug / Type	Formulation	QbD Tool Used	Optimized Parameters	Outcome
Curcumin (Herbal)	Liposome	Box–Behnken Design	Lipid ratio, sonication time	↑ EE%, ↑ bioavailability
Doxorubicin (Synthetic)	Liposome	Central Composite Design	Drug:lipid ratio, hydration time	↑ Stability, ↑ cytotoxicity
Silymarin (Herbal)	Liposome	Risk Assessment + DoE	Phospholipid type, pH	↑ Stability, ↑ bioavailability
Ecliptine (Herbal)	**Proposed Liposome**	**Box–Behnken Design (Novel)**	**Lipid ratio, hydration temp.**	**↑ Hepatoprotective efficacy**



Fig. 5. QbD Optimization Cycle

6. Challenges, Regulatory Considerations, and Future Prospects of QbD in Liposomal Formulations

6.1 Challenges in Applying QbD to Liposomal Systems

While the Quality by Design (QbD) framework provides a powerful approach to rational formulation development, its practical application to liposomal systems presents several challenges due to the intrinsic complexity of these nanoscale structures.

6.1.1 Complexity of Multivariate Systems- Liposomes are composed of multiple interacting components (e.g., phospholipids, cholesterol, drug molecules, surfactants), and their physicochemical properties are highly sensitive to minor variations in formulation or process parameters. Establishing quantitative relationships between Critical Material Attributes (CMAs), Critical Process Parameters (CPPs), and Critical Quality Attributes (CQAs) can therefore be technically demanding.

6.1.2 Analytical Limitations- Accurate characterization of liposomal CQAs such as particle size distribution, lamellarity, zeta potential, and encapsulation efficiency requires advanced analytical tools (e.g., cryo-TEM, DSC, DLS, and NMR). The lack of standardized analytical protocols and variability in measurement techniques can lead to inconsistent data interpretation across laboratories.

6.1.3 Formulation Stability and Scale-Up- Ensuring physical and chemical stability during storage and scale-up remains a major bottleneck. Factors such as lipid oxidation, vesicle

fusion, and drug leakage can compromise product integrity. Translating lab-scale formulations optimized via DoE into large-scale manufacturing systems often demands re-validation of the design space, increasing development time and cost.

6.1.4 Limited Data on Herbal Actives- Compared to synthetic drugs, herbal bioactives like *Ecliptine* or *Silymarin* exhibit additional variability due to differences in source material, extraction methods, and purity levels. This variability complicates the establishment of reproducible CMAs and requires standardization of phytochemical inputs to ensure consistent quality within the QbD framework.

6.2 Regulatory Considerations for QbD Implementation

Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) strongly encourage the adoption of QbD principles for both new drug applications (NDAs) and generic formulations.

Key regulatory guidelines include:

- **ICH Q8 (R2)** – Pharmaceutical Development
- **ICH Q9** – Quality Risk Management
- **ICH Q10** – Pharmaceutical Quality System
- **ICH Q11** – Development and Manufacture of Drug Substances

Under these frameworks, regulatory submissions incorporating QbD must include:

1. Quality Target Product Profile (QTPP) definition.
2. Identification of CQAs, CMAs, and CPPs.
3. Evidence of systematic risk assessment and DoE optimization.
4. Definition of the Design Space with justification of ranges.
5. A validated Control Strategy for ongoing quality assurance.

The implementation of QbD facilitates regulatory flexibility allowing manufacturers to operate within the approved design space without prior regulatory re-approval, thereby promoting continuous process improvement.

However, specific regulatory guidance for nanomedicines and liposomal systems is still evolving. Agencies emphasize the need for:

- Comprehensive physicochemical characterization.
- In vitro–in vivo correlation (IVIVC) studies.
- Long-term stability and toxicological evaluation.
- Robust risk-based documentation of formulation and process design.

For herbal liposomes, additional documentation on source authentication, standardization, and phytochemical consistency is crucial for regulatory acceptance.

6.3 Future Prospects of QbD in Liposomal Drug Delivery

6.3.1 Integration of Artificial Intelligence (AI) and Machine Learning

Future liposomal development will increasingly leverage AI-driven predictive modeling to refine DoE-based optimization. Machine learning algorithms can analyze large experimental datasets to predict optimal formulation conditions and stability outcomes, further improving design space precision. [39]

6.3.2 Real-Time Monitoring and Process Analytical Technology (PAT)

The adoption of PAT tools enables real-time monitoring of critical attributes such as particle size, turbidity, and pH during manufacturing. Coupled with QbD, PAT ensures tighter process control and early detection of deviations, aligning with the Quality 4.0 paradigm of smart manufacturing. [40]

6.3.3 Expansion to Herbal and Biopharmaceutical Liposomes

The integration of QbD principles into herbal-based liposomal formulations remains underexplored. Applying QbD to phytoconstituents like *Ecliptine*, *Andrographolide*, or *Aloin* can help overcome reproducibility issues inherent to herbal preparations, offering standardized and regulatory-compliant nanomedicines. Similarly, biopharmaceuticals and vaccines encapsulated in liposomes can benefit from QbD-guided optimization for stability and targeted delivery. [40]

6.3.4 Lifecycle Management and Continuous Manufacturing

Future QbD strategies will emphasize lifecycle management, where continuous feedback from manufacturing and post-market surveillance is used to refine product performance. Coupling QbD with continuous manufacturing technologies can streamline production, reduce batch variability, and ensure consistent liposomal quality across global markets.

6.4 Summary

The implementation of QbD in liposomal formulation development offers a transformative shift from empirical formulation toward science- and risk-based design. While challenges remain particularly in analytical standardization, scale-up, and herbal drug variability the future holds significant promise through the integration of digital tools, AI-based analytics, and real-time quality monitoring. As regulatory frameworks evolve to accommodate nanotechnology-based and phytopharmaceutical products, the application of QbD to systems

like Ecliptine-loaded liposomes can set new benchmarks for reproducibility, safety, and therapeutic performance.

CONCLUSION

The implementation of Quality by Design (QbD) principles has revolutionized the development of liposomal drug delivery systems, transforming the process from empirical experimentation into a systematic, science-driven approach. By integrating risk assessment, Design of Experiments (DoE), and design space establishment, QbD enables precise control over the Critical Material Attributes (CMAs), Critical Process Parameters (CPPs), and Critical Quality Attributes (CQAs) that define liposomal performance. Through published examples such as curcumin, doxorubicin, and silymarin liposomes it is evident that QbD not only enhances formulation robustness but also improves bioavailability, stability, and therapeutic efficacy. Despite these advances, the practical application of QbD to herbal-based liposomal systems remains underexplored. Natural compounds like Ecliptine, Aloin, and Andrographolide possess immense pharmacological potential but suffer from poor solubility, instability, and low bioavailability. The adaptation of QbD methodologies to such phytoconstituents could bridge the gap between traditional medicine and modern nanotechnology, offering standardized, reproducible, and regulatory-compliant delivery systems. Looking ahead, the integration of Artificial Intelligence (AI), machine learning, and Process Analytical Technology (PAT) will further enhance QbD's predictive capability, enabling real-time quality assurance and adaptive manufacturing. The evolution toward continuous manufacturing and Quality 4.0 paradigms will reinforce QbD's role in ensuring product consistency, patient safety, and cost-effectiveness.

In summary, QbD-based liposomal formulation represents a holistic approach that ensures product quality by design rather than by testing. Expanding its application to herbal nanoliposomes, particularly Ecliptine-loaded systems, holds significant promise for future pharmaceutical innovation. Continued interdisciplinary collaboration among formulation scientists, analytical chemists, and regulatory experts will be vital to fully realize the potential of QbD in developing next-generation nanomedicines that are safe, effective, and globally acceptable.

REFERENCES-

1. Akbarzadeh, A., et al. (2013). Liposome: Classification, preparation, and applications. Nanoscale Research Letters, 8(1), 102. https://doi.org/10.1186/1556-276X-8-102
2. Immordino, M. L., et al. (2006). Stealth liposomes for cancer therapy: A review. Journal of Drug Delivery, 13(3), 143–151. https://doi.org/10.1080/10717540500484881
3. Bozzuto, G., & Molinari, A. (2015). Liposomes as nanomedical devices. International Journal of Nanomedicine, 10, 975–999. https://doi.org/10.2147/IJN.S68861
4. Allen, T. M., & Cullis, P. R. (2013). Liposomal drug delivery systems: From concept to clinical applications. Advanced Drug Delivery Reviews, 65(1), 36–48. https://doi.org/10.1016/j.addr.2012.09.037
5. Torchilin, V. (2005). Recent advances with liposomes as pharmaceutical carriers. Nature Reviews Drug Discovery, 4, 145–160. https://doi.org/10.1038/nrd1632
6. Pattni, B. S., Chupin, V. V., & Torchilin, V. P. (2015). New developments in liposomal drug delivery. Chemical Reviews, 115(19), 10938–10966. https://doi.org/10.1021/cr500419r
7. Drummond, D. C., et al. (1999). Optimizing liposomes for delivery of chemotherapeutic agents. Journal of Pharmacology and Experimental Therapeutics, 289, 1–15. https://doi.org/10.1124/jpet.289.1.1
8. Sercombe, L., et al. (2015). Advances and challenges of liposome assisted drug delivery. Frontiers in Pharmacology, 6, 286. https://doi.org/10.3389/fphar.2015.00286
9. Sharma, A., & Sharma, U. S. (1997). Liposomes in drug delivery: Progress and limitations. International Journal of Pharmaceutics, 154(2), 123–140. https://doi.org/10.1016/S0378-5173(97)00135-X
10. Lian, T., & Ho, R. J. (2001). Trends and applications of liposome formulations. Journal of Pharmaceutical Sciences, 90(6), 667–680. https://doi.org/10.1002/jps.1036
11. Almeida, A. J., & Souto, E. (2007). Lipid nanoparticles: Physicochemical limitations. European Journal of Pharmaceutics and Biopharmaceutics, 65(3), 299–306. https://doi.org/10.1016/j.ejpb.2006.11.009
12. Laouini, A., et al. (2012). Preparation and characterization of liposomes: Challenges and trends. Colloids and Surfaces B, 95, 11–15. https://doi.org/10.1016/j.colsurfb.2012.02.019
13. Danaei, M., et al. (2018). Liposome stability and drug leakage challenges. Pharmaceutics, 10(3), 119. https://doi.org/10.3390/pharmaceutics10030119
14. Yu, L. (2008). Pharmaceutical Quality by Design: An introduction. AAPS Journal, 10(2), 268–276. https://doi.org/10.1208/s12248-008-9020-2

15. ICH. (2009). Quality by Design – Q8 (R2). https://doi.org/10.1201/9781420084853
16. Rathore, A. S., & Winkle, H. (2009). QbD for biopharmaceuticals. Nature Biotechnology, 27, 26–34. https://doi.org/10.1038/nbt0109-26
17. Lawrence, X., et al. (2009). QbD approach in pharmaceutical development. Journal of Pharmaceutical Innovation, 4(4), 194–202. https://doi.org/10.1007/s12247-009-9067-7
18. Lionberger, R. A. (2008). Quality by design in pharmaceuticals. AAPS Journal, 10(2), 268–276. https://doi.org/10.1208/s12248-008-9020-2
19. Yu, L. X., et al. (2014). Implementation of QbD in drug development. Journal of Pharmaceutical Sciences, 103, 2655–2665. https://doi.org/10.1002/jps.24077
20. Salopek, S., et al. (2015). Role of QbD in pharmaceutical development. Acta Pharmaceutica, 65(4), 403–415. https://doi.org/10.1515/acph-2015-0035
21. Bhattachar, S., et al. (2012). Liposomal QbD optimization using DoE. International Journal of Pharmaceutics, 436, 486–500. https://doi.org/10.1016/j.ijpharm.2012.06.041
22. Beg, S., et al. (2016). QbD-based systematic development of nanoliposomes. Journal of Liposome Research, 27(1), 1–12. https://doi.org/10.3109/08982104.2015.1132732
23. Mohammed, A. R., et al. (2013). QbD-based liposomal formulation development. European Journal of Pharmaceutics and Biopharmaceutics, 84, 228–237. https://doi.org/10.1016/j.ejpb.2012.12.010
24. He, X., et al. (2020). DoE optimization of liposomes. Drug Development and Industrial Pharmacy, 46(3), 389–399. https://doi.org/10.1080/03639045.2019.1701660
25. Nagalingam, A., et al. (2019). QbD-guided development of phytoliposomes. Pharmaceutics, 11(12), 672. https://doi.org/10.3390/pharmaceutics11120672
26. Dai, W., et al. (2014). Factors affecting liposome characteristics: A QbD approach. International Journal of Pharmaceutics, 473, 408–415. https://doi.org/10.1016/j.ijpharm.2014.07.028
27. Barenholz, Y. (2012). Doxil® and QbD insights. Journal of Controlled Release, 160, 117–134. https://doi.org/10.1016/j.jconrel.2012.03.020
28. Wagner, A., et al. (2010). Formulation–process interaction in liposome QbD. Journal of Pharmaceutical Sciences, 99, 4005–4019. https://doi.org/10.1002/jps.22121
29. Anselmo, A. C., & Mitragotri, S. (2016). Nanocarrier design considerations. Bioengineering & Translational Medicine, 1(1), 10–29. https://doi.org/10.1002/btm2.10003
30. Sharma, G., et al. (2020). Risk assessment in liposome formulation. Advanced Drug Delivery Reviews, 165, 39–57. https://doi.org/10.1016/j.addr.2020.04.003

31. Patel, S., et al. (2019). QbD optimized curcumin liposomes. International Journal of Pharmaceutics, 556, 80–89. https://doi.org/10.1016/j.ijpharm.2018.11.058
32. Anand, P., et al. (2007). Bioavailability limitations of curcumin. Molecular Pharmaceutics, 4(6), 807–818. https://doi.org/10.1021/mp700113r
33. Barenholz, Y. (2012). Doxorubicin liposomes—Clinical insight. Journal of Controlled Release, 160, 117–134. https://doi.org/10.1016/j.jconrel.2012.03.020
34. Singh, R., et al. (2021). QbD-based optimization of doxorubicin liposomes. European Journal of Pharmaceutics and Biopharmaceutics, 165, 122–131. https://doi.org/10.1016/j.ejpb.2021.05.003
35. Sharma, S., et al. (2022). QbD-optimized silymarin liposomes. Pharmaceutics, 14(9), 1823. https://doi.org/10.3390/pharmaceutics14091823
36. Kidd, P. (2009). Silymarin clinical pharmacology. Alternative Medicine Review, 14(1), 3–20. https://doi.org/10.1016/j.abb.2008.10.025
37. Polyak, S. J., et al. (2013). Biological potential of silymarin. Antiviral Research, 97(2), 305–312. https://doi.org/10.1016/j.antiviral.2012.12.003
38. Kalejaiye, O., et al. (2022). AI in nanomedicine development. ACS Nano, 16(7), 11245–11268. https://doi.org/10.1021/acsnano.2c03317
39. Rathore, A. S. (2011). PAT for biopharmaceuticals. Biotechnology Progress, 27(4), 968–975. https://doi.org/10.1002/btpr.639
40. Rathore, A. S. (2011). PAT for biopharmaceuticals. *Biotechnology Progress, 27*(4), 968–975. https://doi.org/10.1002/btpr.639